IMV Inc IMV-CA:Toronto Stock Exchange

*Data is delayed | CAD
Last | 4:00 PM EST
4.14quote price arrow up+0.08 (+1.97%)
Volume
121,271
52 week range
1.98 - 9.25

...

Loading . . .

KEY STATS

  • Open4.05
  • Day High4.24
  • Day Low3.99
  • Prev Close4.06
  • 52 Week High9.25
  • 52 Week High Date07/14/20
  • 52 Week Low1.98
  • 52 Week Low Date03/23/20
  • Market Cap215.33M
  • Shares Out67.09M
  • 10 Day Average Volume158,022.82
  • Dividend-
  • Dividend Yield-
  • Beta2
  • 1 Year % Change5.08

RATIOS/PROFITABILITY

  • EPS (TTM)-0.59
  • P/E (TTM)-6.97
  • Fwd P/E (NTM)-
  • EBITDA (MRQ)-
  • ROE (MRQ)-
  • Revenue (MRQ)-
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest IMV Inc News

There is no recent news for this security.

Latest IMV-CA News From Our Partners

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
IMV Inc. is a clinical stage biopharmaceutical company focused on developing cancer immunotherapies and vaccines against infectious diseases, including coronavirus disease 2019 (COVID-19). The Company develops cancer-targeted immunotherapies and vaccines based on the Company’s platform, DPX. The Company’s lead candidate, DPX-Survivac, is a T cell-activating immunotherapy that combines the platform with a cancer target: survivin. Its T cell therapy is evaluated in phase II...
Andrew Sheldon
Chairman
Frederic Ors
Chief Executive Officer
Pierre Labbe CPA
Chief Financial Officer
Address
130 Eileen Stubbs Ave Suite 19
Dartmouth, NS
B3B 2C4
Canada